Munich
+49 89 540 31-178 +49 89 540 31-540 m.epping@heuking.de
Languages
German,
English,
French
Practice groups/Expertise
Consulting focuses
- Medicinal Products Law
- Health Care Compliance
- Law on Advertising of Medical Products
- Life Sciences
- Licensing Law
- Medical device regulation
- Unfair Competition Law
Vita
- Admitted to the bar since 1996
- Education and former activities
- Partner at Taylor Wessing, Munich (Life Sciences Regulatory) 2010-2025
- Partner at Ashurst, Munich, in the field of IP/Life Sciences2005-2010
- Senior Associate at Ashurst, Munich, in the field of IP/Life Sciences2002-2005
- Associate / Senior Associate at Wessing, Munich 1996-2002
- Juris doctor, thesis on “Arbitration agreements in international legal transactions following the reform of German arbitration law”, Ludwig Maximilian University of Munich 1998
- Admission as an attorney-at-law 1996
- Second State Examination, Munich 1995
- First State Examination, Munich 1993
- Maître en droit, mention droit international, Université d’Aix-Marseille III (Paul Cézanne), France 1990
- Law studies at the universities of Mainz, Tübingen, Aix-Marseille III and Munich 1986-1993
Qualifications/current topics
Manja Epping has been advising pharmaceutical, medical device, and biotechnology companies on regulatory and contractual issues for more than 25 years. The main areas of her activity are the drafting and negotiation of complex, cross-border license agreements (out-licensing and inlicensing), research and development collaborations, and manufacturing and distribution agreements. Manja Epping also specializes in litigation at the intersection of regulatory, competition, and intellectual property law.
Affiliations
- International Bar Association (IBA)
- Fachausschuss für Arznei- und Lebensmittelrecht (GRUR)
- Arbeitskreis Life Sciences (LES)
Publications
2025
EU Reform: Trilogue on the Pharma Package
Update Health Care & Life Sciences 9/2025,
together with
Miriam Steinhart, LL.M. (The University of Edinburgh)
Standardisierung als Standortfaktor? Standardvertragsklauseln im Arzneimittelrecht
Platform Life Sciences, Biotechnology Edition 2/2025 p. 70 ff,
together with
Dr. Stefanie Greifeneder
, Sarah Aschenbrenner
GCEU overturns extension of regulatory market protection for Tecfidera
Update Health Care & Life Sciences 8/2025, October 15, 2025,
together with
Christoph Behm
Focus on MDR and IVDR: European Commission Launches Call for Evidence
Update Health Care & Life Sciences 6/2025,
together with
Miriam Steinhart, LL.M. (The University of Edinburgh)
The use of AI in clinical trials
Venture Capital Magazin, Impact Life Sciences, April 2025, p. 14 f.,
together with
Dr. Stefanie Greifeneder
2024
Forschungskollaborationen von Life-Sciences-Start-ups – Tipps aus der Rechtsberatungspraxis
Plattform Life Sciences, Biotechnology issue 2/2024, p. 78 ff.,
together with
Dr. Stefanie Greifeneder
Lectures
2025
Impulsvortrag zu Guten Forschungsbedingungen als Grundlage für Investments
Finance Day, October 23, 2025
Vertragsgestaltung in den Life Sciences
Workshop der BioM Biotech Cluster Development GmbH, July 23, 2025, Munich,
together with
Dr. Stefanie Greifeneder
, Sarah Aschenbrenner
The Transparency Tightrope: Balancing Innovation, Regulation, and IP Protection in a New Era
Life Sciences Patent Network (LSPN) North America, Panel presentation, May 2025, Boston (USA), together with E. Ehlich, L. Flanagan and C. Rodrigo
1970
Regulatory Exclusivity Update in Europe and the USA and the Interplay with IP Strategy
Life Science Strategy Summit on IP & Exclusivity, panel presentation, October 2024, Munich, together with representatives from Cooley, UCB, and Polpharma Biologics